A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03901963

Study #:
STUDY00144234

Start Date:
Mar 04, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03901963

View Complete Trial Details & Eligibility at ClinicalTrials.gov